TNGX R&D to Revenue
Tango Therapeutics Inc · R&D to Revenue
TNGX R&D to Revenue
Latest reported211.86%period ending
TNGX FY R&D/Revenue (130.93% → 211.86%)
Latest values, visible window
High-resolution chart · PNG
TNGX r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 211.8572% | |
| 342.0999% | |
| 315.3777% | |
| 426.0097% | |
| 209.5891% | |
| 652.965% | |
| 130.9343% |